Get involved

Join us as we strive to make a healthier future

Powerful partnerships help drive our research for the greater good

The Institute for Glycomics has a broad portfolio of technologies and services available to industry, investors and academic organisations.

It has a management framework and expert personnel in place to meet industry demands and has successfully co-developed products using its translational capability and specialised facilities from concept to market.

To get in touch directly with our Business Team, e-mail

Technologies available

Novel therapeutics for hand, foot & mouth disease

Find out more

Disruptive peptide anti-cancer drug candidates

Find out more


A parasite vaccine platform for babesiosis

Find out more


Development of a whole parasite malaria vaccine

Find out more

Strep A

Novel therapeutics to treat group A strep and STSS

Find out more

Novel treatment for gonorrhea

A novel treatment for gonorrhoea in females

Find out more

A2CG revised image

Australian Centre for Cancer Glycomics (A2CG)

Find out more

Tiralongo commercialisation

Label-free detection technology

Find out more

Gonnoccocal vaccine platform

Gonococcal vaccine portfolio

Find out more


Immunomodulatory Evaluation Platform

Find out more

For Industry

The Institute for Glycomics has a portfolio of discovery to Phase 1 technologies and novel technology platforms available for licensing and co-development. It has successfully co-developed several of its drug and vaccine assets from preclinical stage to Phase 2 human clinical trials through industry partnerships.

For investors

The Institute has a suite of technology packages available for immediate investment.

The Institute is experienced in negotiating and managing a range of investment types.

Success stories

Sienna Deal

Commercialisation of novel cancer diagnostic tool

Institute for Glycomics and the University of Adelaide have entered into an exclusive licensing deal with Sienna Cancer Diagnostics Ltd to commercialise a novel cancer diagnostic tool.

Find out more

CGP signing

New drug to fight human parainfluenza virus

Griffith University's Institute for Glycomics and China Grand Pharma sign landmark deal to develop new drug for parainfluenza virus (hPIV)

Find out more

Lara Paradigm

Promising Phase 2 human clinical trial results

Institute for Glycomics and Melbourne-based company Paradigm Biopharmaceuticals Limited have reported impressive results from their Phase 2A clinical trials of a new drug candidate to treat viral arthritis.

Find out more

Joe new

Mushroom extracts could offer an immune cell boost

Research conducted by the Institute for Glycomics and Integria Healthcare has found that a combination of mushroom extracts is able to help boost the immune system.

Find out more

World’s largest commercial glycan array launched

The Institute for Glycomics has partnered with Dextra Laboratories to launch the world’s largest commercial glycan array and bioanalytical service offering.

Find out more

Ross River virus battle breakthrough

Research conducted by Griffith and Paradigm Biopharmaceuticals has uncovered a potential new treatment in the battle against alphavirus infections.

Find out more

Strep A vaccine partnership raises hope

Griffith's Institute for Glycomics has partnered with Chinese pharmaceutical Olymvax Biopharmaceuticals Inc. for a new needle-free vaccine targeted at Streptococcus A infections, the cause of strep throat and rheumatic heart disease.

Find out more

Sepsis success story

Curbing the impact of sepsis and septic shock

The Institute for Glycomics partners with Sirtex Pty Ltd to develop an anti-sepsis drug candidate.

Find out more

Want to know more?

Get in touch with the Institute for Glycomics